PE20130307A1 - Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv - Google Patents
Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcvInfo
- Publication number
- PE20130307A1 PE20130307A1 PE2012002419A PE2012002419A PE20130307A1 PE 20130307 A1 PE20130307 A1 PE 20130307A1 PE 2012002419 A PE2012002419 A PE 2012002419A PE 2012002419 A PE2012002419 A PE 2012002419A PE 20130307 A1 PE20130307 A1 PE 20130307A1
- Authority
- PE
- Peru
- Prior art keywords
- quinolinyl
- derivative
- thiazolil
- oxi
- powerful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 2
- -1 2-THIAZOLYL-4-QUINOLINYL-OXY Chemical class 0.000 abstract 1
- 229910016523 CuKa Inorganic materials 0.000 abstract 1
- 101800001098 Serine protease NS3 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA SAL DE SODIO CRISTALINA DE UN DERIVADO DE 2-TIAZOLIL-4-QUINOLINIL-OXI DE FORMULA (1) QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X EN POLVO QUE COMPRENDE PICOS A 5,4; 6,5; 8,7; 10,1; 11,9; 13,0; 18,2; 20,2 Y 24,7 GRADOS 2THETA CUANDO SE MIDE USANDO RADIACION CuKa. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA SERINA PROTEASA NS3 DEL VIRUS DE LA HEPATITIS C SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES CAUSADAS POR EL VIRUS DE LA HEPATITIS C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9729108P | 2008-09-16 | 2008-09-16 | |
| US15082609P | 2009-03-09 | 2009-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130307A1 true PE20130307A1 (es) | 2013-03-22 |
Family
ID=41268627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002419A PE20130307A1 (es) | 2008-09-16 | 2009-09-14 | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv |
| PE2011000636A PE20110388A1 (es) | 2008-09-16 | 2009-09-14 | Formas cristalinas de un derivado de peptido como inhibidores de hcv |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000636A PE20110388A1 (es) | 2008-09-16 | 2009-09-14 | Formas cristalinas de un derivado de peptido como inhibidores de hcv |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8232293B2 (es) |
| EP (2) | EP2331538B1 (es) |
| JP (2) | JP5520301B2 (es) |
| KR (1) | KR101653550B1 (es) |
| CN (1) | CN102159571B (es) |
| AR (1) | AR073298A1 (es) |
| AU (1) | AU2009293494B2 (es) |
| BR (1) | BRPI0918513A2 (es) |
| CA (1) | CA2737055C (es) |
| CL (1) | CL2011000558A1 (es) |
| CO (1) | CO6351741A2 (es) |
| CY (1) | CY1115253T1 (es) |
| DK (1) | DK2331538T3 (es) |
| EA (1) | EA018603B1 (es) |
| EC (1) | ECSP11010878A (es) |
| ES (1) | ES2474992T3 (es) |
| HR (1) | HRP20140666T1 (es) |
| IL (1) | IL210345A (es) |
| MA (1) | MA32633B1 (es) |
| ME (1) | ME01831B (es) |
| MX (1) | MX2011002828A (es) |
| MY (1) | MY153093A (es) |
| NZ (2) | NZ591013A (es) |
| PE (2) | PE20130307A1 (es) |
| PL (1) | PL2331538T3 (es) |
| PT (1) | PT2331538E (es) |
| RS (1) | RS53292B (es) |
| SG (1) | SG189740A1 (es) |
| SI (1) | SI2331538T1 (es) |
| TW (1) | TWI471323B (es) |
| UY (1) | UY32119A (es) |
| WO (1) | WO2010033444A1 (es) |
| ZA (1) | ZA201100096B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| AU2009293494B2 (en) | 2008-09-16 | 2014-04-24 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
| AU2009293493B2 (en) | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| US9522068B2 (en) * | 2009-03-13 | 2016-12-20 | The University Of Toledo | Minimally invasive collapsible cage |
| US20120142929A1 (en) * | 2009-03-19 | 2012-06-07 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
| JP5647673B2 (ja) | 2009-05-05 | 2015-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブロモ置換キノリンの調製方法 |
| UA104195C2 (ru) | 2009-07-07 | 2014-01-10 | Берингер Ингельхайм Интернациональ Гмбх | Фармацевтическая композиция ингибитора протеазы вируса гепатита c |
| CA2779244A1 (en) | 2009-10-30 | 2011-05-05 | Boehringer Ingelheim International Gmbh | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| CA2813093A1 (en) * | 2010-09-30 | 2012-04-05 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| CN103380132B (zh) | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EA201490837A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| BR112014017058A8 (pt) | 2012-01-12 | 2017-07-04 | Boehringer Ingelheim Int | formulações farmacêuticas estabilizadas de um potente inibidor de hcv |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| KR20150129005A (ko) * | 2013-03-15 | 2015-11-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 무정형 상태의 hcv 억제제의 고체 경구 투여 제형 |
| BR112015021768A2 (pt) | 2013-03-15 | 2016-02-02 | Gilead Sciences Inc | inibidores do vírus da hepatite c |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| WO2022107182A1 (en) * | 2020-11-18 | 2022-05-27 | University Of Petra | A composition of fentanyl and fatty acids, and a method of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE398448T1 (de) | 1993-09-28 | 2008-07-15 | Scherer Gmbh R P | Herstellung von weichgelatinekapseln |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
| UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| EA009295B1 (ru) | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения в качестве ингибиторов вируса гепатита с |
| EP1753775B1 (en) * | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
| AU2009293494B2 (en) * | 2008-09-16 | 2014-04-24 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2009
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en not_active Ceased
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko not_active Expired - Fee Related
- 2009-09-14 RS RS20140230A patent/RS53292B/sr unknown
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
-
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
-
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
-
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
-
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130307A1 (es) | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv | |
| EA200970805A1 (ru) | Ингибиторы серинпротеаз для лечения hcv инфекций | |
| CY1113752T1 (el) | Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv | |
| CL2004001161A1 (es) | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. | |
| DOP2009000094A (es) | Inhibidores de la proteasa ns3 del hcv | |
| CO6450600A2 (es) | Inhibidores de anillo fusionado de hepatitis c | |
| CL2013003171A1 (es) | Compuesto macrociclico derivado de prolina inhibidor de la proteasa serina ns3; su composicion farmaceutica; y su uso en el tratamiento de una infeccion viral, en particular una infeccion causada por el virus de la hepatitis c (vhc). | |
| CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
| ECSP088258A (es) | Inhibidores de serina proteasas | |
| CO6390077A2 (es) | Inhibidores de hacv ns5a | |
| PE20080123A1 (es) | Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c | |
| CY1112107T1 (el) | Νεα ενωση πυριδαζινης και χρηση αυτης | |
| MY164469A (en) | Hcv ns3 protease inhibitors | |
| ECSP088367A (es) | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c | |
| EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
| UY29016A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
| PE20140109A1 (es) | Inhibidores del virus de la hepatitis c | |
| ECSP13012552A (es) | Formas en estado sólido de un potente inhibidor del vch. | |
| UA90909C2 (en) | Hcv ns3 protease inhibitors | |
| UA106592C2 (uk) | Кристалічна форма 2-тіазоліл-4-хінолінілоксипохідного, активного інгібітора hcv | |
| PH12015502258A1 (en) | Solid oral dosage formulation of hcv inhibitor in the amorphous state | |
| DOP2005000220A (es) | Derivados de indol tetraciclicos como agentes antiviricos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |